NKGEN BIOTECH, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 USD | +2.29% |
|
+5.51% | -51.27% |
| Jul. 01 | NKGen Biotech, Inc.(NasdaqGM:NKGN) added to Russell Microcap Growth Index | CI |
| Jul. 01 | NKGen Biotech, Inc.(NasdaqGM:NKGN) added to Russell 3000E Index | CI |
Financials (USD)
| Sales 2022 | 77K | Sales 2023 | - | Capitalization | 60.19M |
|---|---|---|---|---|---|
| Net income 2022 | -26M | Net income 2023 | -83M | EV / Sales 2022 | - |
| Net Debt 2022 | 11.92M | Net Debt 2023 | 19.9M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5.79
x | P/E ratio 2023 |
-0.51
x | Employees | 63 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 38.88% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.29% | ||
| 1 week | +5.51% | ||
| Current month | +5.51% | ||
| 1 month | -2.19% | ||
| 3 months | -2.90% | ||
| 6 months | -51.27% | ||
| Current year | -51.27% |
1 week
1.21
1.34
1 month
1.171.52
Current year
0.784.06
1 year
0.7812.88
3 years
0.7812.88
5 years
0.7812.88
10 years
0.7812.88
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 1.34 | +2.29% | 43,871 |
| 24-07-03 | 1.31 | +8.26% | 47,441 |
| 24-07-02 | 1.21 | -4.72% | 39,937 |
| 24-07-01 | 1.27 | 0.00% | 39,148 |
| 24-06-28 | 1.27 | +2.42% | 51,306 |
End-of-day quote Nasdaq, July 04, 2024
More quotes
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimerâs disease (AD) and Parkinsonâs disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
| 1st Jan change | Capi. | |
|---|---|---|
| -51.27% | 33.35M | |
| +18.97% | 45.34B | |
| +41.98% | 40.42B | |
| -10.06% | 37.92B | |
| +31.15% | 31.75B | |
| -7.79% | 27.71B | |
| +13.32% | 26.52B | |
| +43.05% | 13.96B | |
| +31.28% | 12.44B | |
| -7.41% | 11.26B |
- Stock Market
- Equities
- NKGN Stock
